ZAI LAB LIMITED Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-05-19: Reporting owner Du Ying; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-05-18: Reporting owner Du Ying; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-05-15: Reporting owner Du Ying; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-05-14: Reporting owner Du Ying; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
ZLAB insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −261,092 0 owned after | $1.74 exercise price | $18.37 | 2026-05-21 |
| 2026-05-18 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 261,092 owned after | $1.74 exercise price | $18.86 | 2026-05-19 |
| 2026-05-15 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 311,092 owned after | $1.74 exercise price | $20.59 | 2026-05-19 |
| 2026-05-14 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 361,092 owned after | $1.74 exercise price | $20.33 | 2026-05-15 |
| 2026-05-13 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 411,092 owned after | $1.74 exercise price | $20.47 | 2026-05-15 |
| 2026-05-11 | Wang Yizhe Officer (Operating Partner) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +136,819 136,819 owned after | $20.32 exercise price | $19.59 | 2026-06-08 |
| 2026-03-11 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +353,430 353,430 owned after | $19.34 exercise price | $19.07 | 2026-03-16 |
| 2026-03-10 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −261,092 461,092 owned after | $1.74 exercise price | $19.46 | 2026-03-12 |
| 2026-03-09 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 722,184 owned after | $1.74 exercise price | $19.12 | 2026-03-10 |
| 2026-03-06 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 772,184 owned after | $1.74 exercise price | $19.54 | 2026-03-10 |
| 2026-03-05 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 822,184 owned after | $1.74 exercise price | $19.30 | 2026-03-06 |
| 2026-03-04 | Smiley Joshua L Officer (See Remarks) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +103,950 103,950 owned after | $19.27 exercise price | $19.27 | 2026-03-16 |
| 2026-03-04 | Edmondson Frazor Titus III Officer (Chief Legal Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +83,160 83,160 owned after | $19.27 exercise price | $19.27 | 2026-03-16 |
| 2026-03-04 | Chen Yajing Officer (Chief Financial Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +83,160 83,160 owned after | $19.27 exercise price | $19.27 | 2026-03-16 |
| 2026-03-04 | Amado Rafael Officer (See Remarks) | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +103,950 103,950 owned after | $19.27 exercise price | $19.27 | 2026-03-16 |
| 2026-03-04 | Du Ying Director, Officer (Chairperson & CEO) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 872,184 owned after | $1.74 exercise price | $19.27 | 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |